Can a Four-Drug cocktail tame inoperable liver cancer?
NCT ID NCT07746960
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial is testing whether a combination of chemotherapy, immunotherapy, and a targeted therapy can help people with unresectable hepatocellular carcinoma, a type of liver cancer that cannot be removed with surgery. Participants receive a regimen of two chemotherapy drugs (oxaliplatin and raltitrexed) plus an immunotherapy drug (penpulimab) and an oral targeted therapy (anlotinib). The study aims to see how well this combination shrinks tumors and how safe it is for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of intravenous chemotherapy (oxaliplatin and raltitrexed), an immunotherapy drug (penpulimab), and an oral targeted therapy (anlotinib)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with liver cancer that cannot be removed by surgery, potentially shrinking tumors and extending life.
- What could go wrong
- This is an early-stage, small trial, so the benefits are uncertain. The combination may cause significant side effects, and the response rate could be lower than hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new imaging agent could tell doctors which liver cancers will resist immunotherapy
- Can adding a fourth drug shrink large liver tumors that invade the portal vein?
- Chemo-loaded microspheres aim to starve liver tumors from within
- New combo therapy aims to stop liver cancer in its tracks
- New combo therapy aims to shrink liver tumors in Hard-to-Treat patients
- New combo shrinks untouchable liver tumors, opens door to surgery